ALS drug trial halted early: what happened?

NCT ID NCT03757351

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an experimental drug called DNL747 in 15 people with ALS to see if it was safe and how the body processed it. The study was terminated before completion, so we don't have full results. It was a small, short-term safety study, not a test of whether the drug can treat ALS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNL747
What this could lead to: If successful, this could point toward a treatment to slow ALS progression, but the trial was terminated early, so no conclusions can be drawn.
What could go wrong: This was a very early (Phase 1) safety study with only 15 participants, and it was terminated before completion. There is no evidence yet that DNL747 works for ALS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Bioclinica

Orlando, Florida, 32806, United States
CHDR

Leiden, South Holland, 2333, Netherlands
PRA Health Sciences

Salt Lake City, Utah, 84124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.